araag2/HINT huggingface dataset:
Clinical trial NCT01115569 (phase 3, status: completed)
Conditions: chronic pain
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: hydrocodone bitartrate
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have a diagnosed moderate to severe chronic pain condition treated with
             around-the-clock opioids for at least the past 3 months or in the Investigator's
             opinion qualify for around-the-clock opioid therapy for treatment of their pain

          -  Subjects must have been taking opioids at least 5 days/week for the past month at an
             average daily dose of at least 30 mg hydrocodone

          -  Subjects must be able to complete study procedures and attend clinic visits for 6 to
             12 months

          -  Females subjects of childbearing potential must have a negative urine pregnancy test
             at the Screen Visit, and must consent to use a medically-acceptable method of
             contraception throughout the entire study period.

          -  Subjects must have had an adequate medical evaluation for the treatment of their
             underlying painful condition and appropriate primary medical/surgical therapies for
             the underlying condition

          -  Subjects must voluntarily provide written informed consent

        Exclusion Criteria:

          -  Any clinically significant condition that would, in the opinion of the investigator,
             preclude study participation or interfere with the assessment of pain or increase the
             risk of opioid-related adverse events (AEs)

          -  A medical condition that, in the opinion of the Investigator, would compromise the
             subject's ability to swallow, absorb, metabolize, or excrete study drug

          -  A surgical procedure for pain within the last 3 months

          -  Uncontrolled blood pressure, i.e., a sitting systolic blood pressure >180 mm Hg or <90
             mm Hg, and/or a sitting diastolic blood pressure >120 mm Hg or <50 mm Hg at Screening

          -  A body mass index (BMI) > 45 kg/m2

          -  A hospital anxiety and depression scale (HADS) score of >12 in either depression or
             anxiety subscales or an established history of any psychiatric disorder that is poorly
             controlled

          -  A clinically significant abnormality in clinical chemistry, hematology or urinalysis
Clinical trial NCT00156104 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine, asenapine, haloperidol
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Currently suffering from an acute exacerbation of schizophrenia. Caregiver required.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable medical condition. Have any other pyschiatric disorder
             other than schizophrenia as a primary diagnosis.
Clinical trial NCT00276484 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: atorvastatin, atorvastatin, ezetimibe
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with LDL-C >70 mg/dL & on a stable dose of atorvastatin 40 mg

        Exclusion Criteria:

          -  Pregnant or lactating women or intending to become pregnant

          -  Patient with sensitivity or intolerance to ezetimibe or atorvastatin
Clinical trial NCT00219232 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: rivastigmine transdermal patch
SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who fulfilled the inclusion and exclusion criteria as listed in the study
             CENA713D2320 and have completed the double-blind treatment phase on study medication
             without significant protocol violations.
Clinical trial NCT00083889 (phase 3, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: interferon-alfa, su011248
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed renal cell carcinoma of clear cell histology with metastases

          -  Evidence of measurable disease by radiographic technique

          -  Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

        Exclusion Criteria:

          -  Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC

          -  History of or known brain metastases

          -  Serious acute or chronic illness or recent history of significant cardiac abnormality
Clinical trial NCT01781702 (phase 3, status: completed)
Conditions: pelubiprofen, celebrex, rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: pelubiprofen 30 mg, celebrex 200 mg
SMILES: [H]\C(C1=CC=C(C=C1)C(C)C(O)=O)=C1\CCCCC1=O, CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Adult males/Females aged 18~80 years

          2. Patient who are taking NSAIDs for the treatment of rheumatoid arthritis

          3. Patients who belong to ACR functional class 1, 2, 3

        Exclusion Criteria:

          1. Patients who belong to ACR functional class 4

          2. Patients who are hypersensitive to clinical trial medicines or excipient

          3. Patients who have experience of Cerebrovascular bleeding, bleeding disorder
Clinical trial NCT01029262 (phase 3, status: completed)
Conditions: anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older

          -  Diagnosis of low or intermediate-1 risk Myelodysplastic (MDS) with any chromosome
             karyotype except del 5q[31]

          -  Anemia that requires red blood cell transfusions

          -  Resistant to erythropoiesis stimulating agents (ESAs) or blood erythropoietin level >
             500 mU/mL

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

          -  Must agree to follow pregnancy precautions as required by the protocol.

          -  Must agree to receive counseling related to teratogenic and other risks of
             lenalidomide

          -  Must agree not to donate blood or semen

          -  Must be willing to consent to two or more bone marrow aspirate procedures to be
             completed during study

        Exclusion Criteria:

          -  Subjects previously receiving immunomodulating or immunosuppressive agents, or
             epigenetic or deoxyribonucleic acid (DNA) modulation agents

          -  Allergic reaction to thalidomide

          -  Renal insufficiency creatinine clearance (CrC1)<40 mL/min by Cockcroft-Gault method)

          -  Prior history of cancer, other than MDS, unless the subject has been free of the
             disease for ≥ 5 years. (Basal cell carcinoma of the skin, carcinoma in situ of the
             cervix, or stage Tumor (T) 1a or T1b prostate cancer is allowed)

          -  Absolute neutrophil count (ANC) < 500/uL

          -  Platelets < 50,000/uL

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3X upper limit of
             normal

          -  Uncontrolled hyperthyroidism or hypothyroidism

          -  Significant neuropathy

          -  Prior stem cell transplantation

          -  Anemia due to reasons other than MDS

          -  History of deep venous thrombosis (DVT) or pulmonary embolus (PE) within past 3 years

          -  Significant active cardiac disease within the past 6 months

          -  Known Human Immunodeficiency Virus (HIV) infection; known Hepatitis C infection or
             active Hepatitis B infection
Clinical trial NCT01040780 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: icotinib, gefitinib
SMILES: C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Confirmed NSCLC with Histology or cytology; advanced （IIIb/IV).

          2. Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior
             chemotherapy must be completed at least 4 weeks before study enrollment; =.

        Exclusion Criteria:

        1. Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
        erbitux.
Clinical trial NCT00378833 (phase 3, status: completed)
Conditions: hypercholesterolemia, hyperlipidemia
ICD codes: E78.01, E78.00, Z83.42, E78.2, E78.49, E78.5
Drugs: niacin (+) laropiprant, niacin
SMILES: CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1, OC(=O)C1=CN=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is an appropriate candidate for niacin therapy (at risk for heart disease) and
             triglycerides < 500 mg/dL

        Exclusion Criteria:

          -  Patients with a history of any cardiovascular event directly linked to atherosclerosis
             with a low density lipoprotein-cholesterol (LDL-C) >/= 130 mg/dL and/or not on a
             statin

          -  Patients with diabetes and LDL-C >/= 130 mg/dL. Patients with >/= 2 heart disease risk
             factors and LDL-C >/= 160 mg/dL.

          -  Patients who have had a cardiovascular event (e.g., heart attack, stroke) within the
             previous 3 months.
Clinical trial NCT00375492 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes for at least 6 months

          -  Have been treated with a stable dose of the following for at least 6 weeks prior to
             screening: *immediate or extended release metformin, or *a sulfonylurea, or *a
             fixed-dose sulfonylurea/metformin combination therapy

          -  Have an HbA1c of 6.6% to 10.0%, inclusive

          -  Have a Body Mass Index (BMI) of 25 kg/m^2 to 39.9 kg/m^2, inclusive

        Exclusion Criteria:

          -  Are treated with any of the following excluded medications: *exogenous insulin,
             thiazolidinedione, or alpha-glucosidase inhibitor for more than 1 week within 6 weeks
             of screening; *Symlin injection at any time; * Byetta injection within 3 months of
             screening or discontinuation of therapy at any time due to adverse reaction; *drugs
             that directly affect gastrointestinal motility; *use of a weight loss drug (including
             those available over the counter) within 3 months of screening; *chronic (lasting
             longer than 2 weeks) systemic corticosteroids (excluding topical, intranasal, and
             inhaled preparations) by oral, intravenous, or intramuscular route within 2 months of
             screening

          -  Have conditions contraindicating metformin and/or sulfonylurea use

          -  Have had a change in lipid-lowering agents within 6 weeks of screening

          -  Have received glucagon-like peptide-1 (GLP-1) analogs, or dipeptidyl peptidase-IV
             inhibitors (DPP-IV inhibitors) or have previously participated in this study

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry
Clinical trial NCT00325364 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: human insulin inhalation powder, injectable insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Non smoker

          -  Normal lung function

        Exclusion Criteria:

          -  Pulmonary, hepatic, or renal disease

          -  Congestive heart failure

          -  Active malignancy

          -  Systemic glucocorticoid therapy
Clinical trial NCT00122837 (phase 3, status: completed)
Conditions: anxiety disorder
ICD codes: F41.1, F41.9, F40.9, F43.22, F41.0, F93.0, F12.980
Drugs: duloxetine, venlafaxine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female outpatients at least 18 years of age, presenting with generalized
             anxiety disorder (GAD).

        Exclusion Criteria:

          -  Any current and primary Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition (DSM-IV) Axis I diagnosis other than GAD. Patients diagnosed with major
             depressive disorder within the past 6 months -or- patients diagnosed with panic
             disorder, post-traumatic stress disorder, or an eating disorder within the past year
             -or- obsessive-compulsive disorder, bipolar affective disorder, psychosis factitious
             disorder, or somatoform disorders during their lifetime

          -  The presence of an Axis II disorder or history of antisocial behavior, which in the
             judgement of the investigator would interfere with compliance with study protocol

          -  Have previously completed or withdrawn from this study or any other study
             investigating duloxetine or have previously been treated with duloxetine

          -  History of alcohol or any psychoactive substance abuse or dependence (as defined in
             the DSM-IV-TR) within the past 6 months
Clinical trial NCT00093899 (phase 3, status: completed)
Conditions: hyperlipidemia, hypercholesterolemia, hypertriglyceridemia
ICD codes: E78.2, E78.49, E78.5, E78.01, E78.00, Z83.42
Drugs: ezetimibe (+) simvastatin
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women 18-79 years of age with high cholesterol and high triglycerides.

        Exclusion Criteria:

          -  Individuals who do not meet specific cholesterol or triglyceride levels as required by
             the study.
Clinical trial NCT00085709 (phase 3, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: gemtuzumab ozogamicin, cytosine arabinoside, daunomycin
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Morphologically confirmed acute myeloid leukemia (AML) by bone marrow aspiration and
             biopsy* within the past 14 days

               -  No M3 disease NOTE: *Patients with marked leukocytosis may be registered before
                  the availability of biopsy results if the absolute blast count is ≥ 100,000
                  cells/µL

          -  No blastic transformation of chronic myelogenous leukemia

          -  No pre-existing hematologic disorder evolving to AML (e.g., myelodysplasia or
             secondary leukemia)

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 60

        Performance status

          -  Zubrod 0-3

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  AST and ALT ≤ 3 times ULN

          -  No known hepatitis B or C infection

          -  No known liver disease

        Renal

          -  Not specified

        Cardiovascular

          -  LVEF ≥ 50% by MUGA or echocardiogram

          -  No unstable cardiac arrhythmias

          -  No unstable angina

        Other

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer currently in complete remission

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior systemic chemotherapy

               -  Prior hydroxyurea to control high cell counts allowed

          -  No more than 1 prior dose of intrathecal chemotherapy for acute leukemia

          -  Concurrent intrathecal chemotherapy allowed during induction therapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
Clinical trial NCT00397189 (phase 3, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: circadin, placebo circadin
SMILES: COC1=CC2=C(NC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female and aged 18-80 years.

          -  Are willing to take a 6-SMT level evaluation test.

          -  Suffering from primary insomnia according to DSM-IV. criteria (307.42 primary
             insomnia, Appendix 24.3) .

          -  Sleep latency of at least 20 minutes.

          -  Have not been using benzodiazepines (BZD) and non-BZD hypnotics for the past 2 weeks
             or more.

          -  Have not been using psychotropic treatments for the past 3 months or more.

          -  Are stabilized on non-psychotropic treatments for more than 1 month.

          -  Are willing to sign a written informed consent to participate in the study.

        Exclusion Criteria:

          -  Use of benzodiazepines or other hypnotics (including psychotropic treatments) during
             the study and preceding two weeks.

          -  Alcohol intake more than 30 g of pure alcohol per day and any intake after lunch-time.

          -  Pharmacological immunosuppression.

          -  Participation in a clinical trial with any investigational agent within two months
             prior to study enrollment.

          -  According to DSM IV, subjects belonging to the following groups are excluded: 780.59
             (breathing related sleep disorder); 307.45 (circadian rhythm sleep disorder); 307.47
             (dyssomnia not otherwise specified); 780.xx (sleep disorder due to general medical
             condition).

          -  Severe neurological, psychiatric disorders (especially psychosis, anxiety and
             depression) and alcoholism.

          -  Other serious diseases that could interfere with patient assessment.

          -  Pregnant or breast feeding women.
Clinical trial NCT01242215 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, sulfonylurea
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients receiving with sulfonylurea mono-therapy for at least 4 weeks

          -  HbA1c value between 7.0 and 9.5%

          -  Body Mass Index (BMI) 20.0 - 45.0 kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Serum creatinine > upper limit of normal

          -  Proteinuria (albumin/creatinine ratio > 300mg/g)

          -  Dysuria and/or urinary tract infection, genital infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases
Clinical trial NCT00332241 (phase 3, status: completed)
Conditions: autistic disorder
ICD codes: F84.0
Drugs: aripiprazole, placebo
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets current Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition
             (DSM-IV) diagnostic criteria for AD and demonstrates serious behavioral problems.
             Diagnosis confirmed by Autism Diagnostic Interview- Revised (ADI-R)

          -  CGI score > = 4 AND and Aberrant Behavior Checklist (ABC) Irritability/Agitation
             subscale score > = 18 at screening and baseline (randomization)

          -  Mental age of at least 18 months

          -  Male or female 6 to 17 years of age, inclusive, at the time of randomization

        Exclusion Criteria:

          -  Patients considered treatment resistant to neuroleptic medication based on lack of
             therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks
             each.

          -  Patients previously treated and not responding to aripiprazole treatment

          -  The patient is currently diagnosed with another disorder on the autism spectrum,
             including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or
             Childhood Disintegrative Disorder

          -  Current diagnosis of bipolar disorder, psychosis, or schizophrenia, or major
             depression

          -  A seizure in the past year

          -  History of severe head trauma or stroke

          -  Patients undergoing non-pharmacologic therapies (e.g., psychotherapy, behavioral
             modification) must have started at least 2 months prior to the initial screening visit
             and must remain in a consistent treatment program for the duration of the study.
Clinical trial NCT00660907 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, glipizide, metformin hydrochloride
SMILES: CN(C)C(=N)NC(N)=N, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes

          -  Treated with oral anti-diabetic drug therapy therapy including Metformin for at least
             8 weeks prior to enrolment

          -  HbA1c >6.5% and </=10%

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Insulin therapy within one year of enrolment

          -  Renal (kidney) failure or dysfunction